Rational Herbal and Complementary Interventions for Prevention and Treatment of Urological Disorders in Men

  • Mark A. MoyadEmail author
Part of the Current Clinical Urology book series (CCU)


Almost all major and minor urologic conditions are impacted positively and negatively by certain lifestyle changes and dietary supplements. Some of these complementary interventions have potential positive impacts independently or in combination with conventional therapy, others have no activity, and some could negatively impact treatment and overall health. Few specialties have arguably invested more finances and energy and effort in determining whether certain lifestyle changes and dietary supplements impact a variety of medical conditions compared to urology. Therefore, a rapid review of potentially efficacious and nonefficacious complementary medicine interventions is needed. It should be of interest to the clinician that the heart healthiest complementary medicine recommendations have generally served as the safest and most potentially effective interventions in urology from BPH, chronic nonbacterial prostatitis, interstitial cystitis, multiple urologic cancers, male infertility, male and female sexual dysfunction, kidney stones, Peyronie’s disease, and urinary tract infections (UTIs).


Bladder Cancer Dietary Supplement Erectile Dysfunction Benign Prostatic Hyperplasia Plant Sterol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Moyad MA. Calcium oxalate kidney stones: another reason to encourage moderate calcium intakes and other dietary changes. Urol Nurs. 2003;23:310–3.PubMedGoogle Scholar
  2. 2.
    Moyad MA. Step-by-step lifestyle changes that can improve urologic health in men, part I: what do I tell my patients? Prim Care. 2006;33:139–63.PubMedGoogle Scholar
  3. 3.
    Moyad MA. Step-by-step lifestyle changes that can improve urologic health in men, part II: what do I tell my patients? Prim Care. 2006;33:165–85.Google Scholar
  4. 4.
    Moyad MA, Roach 3rd M. Promoting wellness for patients on androgen deprivation therapy: why using numerous drugs for drug side effects should not be first-line treatment. Urol Clin North Am. 2011;38:303–12.PubMedGoogle Scholar
  5. 5.
    Kane CJ, Raheem OA, Bent S, Avins AL. What do I tell patients about saw palmetto for benign prostatic hyperplasia. Urol Clin North Am. 2011;38:261–77.PubMedGoogle Scholar
  6. 6.
    Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51.PubMedGoogle Scholar
  7. 7.
    Lee J, Andriole G, Avins A, et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clin Trials. 2009;6:628–36.PubMedGoogle Scholar
  8. 8.
    Moyad MA. Promoting wellness for patients with prostate cancer, 3rd edn. Ann Arbor: Ann Arbor Media Publishing; 2011.Google Scholar
  9. 9.
    Moyad MA. Lifestyle changes to prevent BPH: heart healthy=prostate healthy. Urol Nurs. 2003;23:439–41.PubMedGoogle Scholar
  10. 10.
    Sea J, Poon KS, McVary KT. Review of exercise and the risk of benign prostatic hyperplasia. Phys Sportsmed. 2009;37:75–83.PubMedGoogle Scholar
  11. 11.
    Parsons JK, Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol. 2009;182:1463–8.PubMedGoogle Scholar
  12. 12.
    Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep. 2010;5:212–8.PubMedGoogle Scholar
  13. 13.
    Moyad MA, Lowe FC. Educating patients about lifestyle modifications for prostate health. Am J Med. 2008;121(8 Suppl 2):S34–42.PubMedGoogle Scholar
  14. 14.
    Parsons JK. Lifestyle factors, bengin prostatic ­hyperplasia, and lower urinary tract symptoms. Curr Opin Urol. 2011;21:1–4.PubMedGoogle Scholar
  15. 15.
    Zhang X, Zhang J, Chen J, et al. Prevalence and risk factors of nocturia and nocturia-related quality of life in the Chinese population. Urol Int. 2011;86:173–8.PubMedGoogle Scholar
  16. 16.
    Wong SY, Woo J, Leung JC, Leung PC. Depressive symptoms and lifestyle factors as risk factors of lower urinary tract symptoms in Southern Chinese men: a prospective study. Aging Male. 2010;13:113–9.PubMedGoogle Scholar
  17. 17.
    Mongiu AK, McVary KT. Lower urinary tract symptoms, bengin prostatic hyperplasia, and obesity. Curr Urol Rep. 2009;10:247–53.PubMedGoogle Scholar
  18. 18.
    Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int. 2008; 101:313–8.PubMedGoogle Scholar
  19. 19.
    Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007; 178:395–401.PubMedGoogle Scholar
  20. 20.
    Jones PJ, AbuMweis SS. Phytosterols as functional food ingredients: linkages to cardiovascular disease and cancer. Curr Opin Clin Nutr Metab Care. 2009; 12:147–51.PubMedGoogle Scholar
  21. 21.
    Berryman CE, Preston AG, Karmally W, Deckelbaum RJ, Kris-Etherton PM. Effects of almond consumption on the reduction of LDL-cholesterol: a discussion of potential mechanisms and future research directions. Nutr Rev. 2011;69:171–85.PubMedGoogle Scholar
  22. 22.
    Aldemir M, Okulu E, Neselioglu S, Erel O, Kayigil O. Pistachio diet improves erectile function parameters and serum lipid profiles in patients with erectile dysfunction. Int J Impot Res. 2011;23:32–8.PubMedGoogle Scholar
  23. 23.
    Guardamagna O, Abello F, Baracco V, et al. Primary hyperlipidemias in children: effect of plant sterol ­supplementation on plasma lipids and markers of ­cholesterol synthesis and absorption. Acta Diabetol. 2011;48(2):127–33.PubMedGoogle Scholar
  24. 24.
    Malinkowski JM, Gehret MM. Phytosterols for dyslipidemia. Am J Health Syst Pharm. 2010;67:1165–73.Google Scholar
  25. 25.
    Hamilton P. Role of ezetimibe in the management of patients with atherosclerosis. Coron Artery Dis. 2009;20:169–74.PubMedGoogle Scholar
  26. 26.
    Dujovne CA, Suresh R, McCrary Sisk C, et al. Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years. Int J Clin Pract. 2008;62:1332–6.PubMedGoogle Scholar
  27. 27.
    Pelton K, Di Vizio D, Insabato L, et al. Ezetimibe reduces enlarged prostate in an animal model of benign prostatic hyperplasia. J Urol. 2010;184:1555–9.PubMedGoogle Scholar
  28. 28.
    Mills IW, Crossland A, Patel A, Ramonas H. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol. 2007;52:503–9.PubMedGoogle Scholar
  29. 29.
    Stamatiou KN, Zaglavira P, Skolarikos A, Sofras F. The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol. 2008;34:555–61.PubMedGoogle Scholar
  30. 30.
    Hall SA, Chiu GR, Link CL, et al. Are statin medications associated with lower urinary tract symptoms in men and women? Results from the Boston Area Community Health (BACH) Survey. Ann Epidemiol. 2011;21:149–55.PubMedGoogle Scholar
  31. 31.
    St Sauver JL, Jacobsen SJ, Jacobson DJ, et al. Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int. 2011;107:443–50.PubMedGoogle Scholar
  32. 32.
    Padayatty SJ, Marcelli M, Shao TC, Cunningham GR. Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab. 1997;82:1434–9.PubMedGoogle Scholar
  33. 33.
    Wilt TJ, MacDonald R, Ishani A. Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int. 1999;83:976–83.PubMedGoogle Scholar
  34. 34.
    Wilt T, Ishani A, MacDonald R, et al. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001043.Google Scholar
  35. 35.
    McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). Clin Evid (online). 2011.Google Scholar
  36. 36.
    Cabeza M, Bratoeff E, Heuze I, et al. Effect of beta-sitosterol as inhibitor of 5-alpha-reductase in hamster prostate. Proc West Pharmacol Soc. 2003;46:153–5.PubMedGoogle Scholar
  37. 37.
    National Cholesterol Education Porgram (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.Google Scholar
  38. 38.
    Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for bengin prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(1):CD001044.Google Scholar
  39. 39.
    McQueen CE, Bryant PJ. Pygeum. Am J Health Syst Pharm. 2001;58:120–3.PubMedGoogle Scholar
  40. 40.
    Suzuki M, Ito Y, Fujino T, et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009;30:227–81.PubMedGoogle Scholar
  41. 41.
    Stewart KM. The African cherry (Prunus africana): can lessons be learned from an over-exploited tree. J Ethnopharmacol. 2003;89:3–13.PubMedGoogle Scholar
  42. 42.
    Edgar AD, Levin R, Constantinou CE, Denis L. A critical review of the pharmacology of the plant extract of Pygeum africanum in the treatment in the treatment of the LUTS. Neurourol Urodyn. 2007;26:458–63.PubMedGoogle Scholar
  43. 43.
    Lopez-Miranda J, Perez-Jimenez F, Ros E, et al. Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaen and Cordoba (Spain) 2008. Nutr Metab Cardiovasc Dis. 2010;20:284–94.PubMedGoogle Scholar
  44. 44.
    Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146–55.PubMedGoogle Scholar
  45. 45.
    Kochikuzhyil BM, Devi K, Fattepur SR. Effect of saturated fatty acid-rich dietary vegetable oils on lipid profile, antioxidant enzymes and glucose tolerance in diabetic rats. Indian J Pharmacol. 2010;42:142–5.PubMedGoogle Scholar
  46. 46.
    Yamagishi K, Iso H, Yatsuya H, et al. for the JACC Study Group. Dietary intake of saturated fatty acids and mortality from cardiovascular disease in Japanese: the Japan Collaborative Cohort Study for Evaluation of Cancer Risk. Am J Clin Nutr. 2010;92:759–65.Google Scholar
  47. 47.
    Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354:557–66.PubMedGoogle Scholar
  48. 48.
    Barry MJ, Meleth S, Lee JY, et al. for the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306:1344–51.Google Scholar
  49. 49.
    Sinescu I, Geavlete P, Multescu R, et al. Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Urol Int. 2011;86:284–9.PubMedGoogle Scholar
  50. 50.
    Debruyne F, Boyle P, Calais Da Silva F, et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol. 2004;45:773–9.PubMedGoogle Scholar
  51. 51.
    Carballido J, Ruiz-Cerda JL, Unda M, et al. Economic evaluation of medical treatment of benign prostatic hyperplasia (BPH) in the specialized care setting in Spain. Application to the cost-effectiveness of two drugs frequently used in its treatment. Actas Urol Esp. 2008;32:916–25.PubMedGoogle Scholar
  52. 52.
    Geavlete P, Multescu R, Geavlete B. Serenoa repens extract in the treatment of benign prostatic hyperplasia. Ther Adv Urol. 2011;3:193–8.PubMedGoogle Scholar
  53. 53.
    Shoskes DA, Zeitlin SI, Shahed A, Raffer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999;54:960–3.PubMedGoogle Scholar
  54. 54.
    Wagenlehner FM, Schneider H, Ludwig M, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomized, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56: 544–51.PubMedGoogle Scholar
  55. 55.
    Asakawa K, Nandachi N, satoh S, et al. Effects of cernitin pollen extract (Cernilton) on inflammatory cytokines in sex-hormone-induced nonbacterial prostatitis rats [in Japanese]. Hinyokika Kiyo. 2001;47: 459–65.PubMedGoogle Scholar
  56. 56.
    Katske F, Shoskes DA, Sender M, Poliakin R, Gagliano K, Rajfer J. Treatment of interstitial cystitis with a quercetin supplement. Tech Urol. 2001;7(1):44–6.PubMedGoogle Scholar
  57. 57.
    Boots AW, Haenen GRMM, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585:325–37.PubMedGoogle Scholar
  58. 58.
    Shoskes DA, Nickel JC. Quercetin for chronic prostatitis/chronic pelvic pain syndrome. Urol Clin North Am. 2011;38:279–84.PubMedGoogle Scholar
  59. 59.
    Giubilei G, Mondaini N, Minervini A, Saieva C, Lapini A, Serni S, Bartoletti R, Carini M. Physical activity of men with chronic prostatitis/chronic pelvic pain syndrome not satisfied with conventional treatments-could it represent a valid option? The physical activity and male pelvic pain trial: a double-blind, randomized study. J Urol. 2007;177:159–65.PubMedGoogle Scholar
  60. 60.
    Pool JL. Role of sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Pract Suppl. 1994;74:13–7.PubMedGoogle Scholar
  61. 61.
    Esch T, Stefano GB. The neurobiology of stress management. Neuro Endocrinol Lett. 2010;31:19–39.PubMedGoogle Scholar
  62. 62.
    McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2005;174(4 Pt 1):1327–433.PubMedGoogle Scholar
  63. 63.
    Grossman HB, Stenzl A, Moyad MA, Droller MJ. Bladder cancer: chemoprevention, complementary approaches and budgetary considerations. Scand J Urol Nephrol Suppl. 2008;218:213–33.PubMedGoogle Scholar
  64. 64.
    Vilensky D, Lawrentschuk N, Hersey K, Fleshner NE. A smoking cessation program as a resource for bladder cancer patients. Can Urol Assoc J. 2011; May 1:1–7, epub ahead of print.Google Scholar
  65. 65.
    Joshu CE, Mondul AM, Meinhold CL, et al. Cigarette smoking and prostate cancer recurrence after prostatectomy. J Natl Cancer Inst. 2011;103(10):835–8.PubMedGoogle Scholar
  66. 66.
    Moyad MA. Obesity, interrelated mechanisms, and exposures and kidney cancer. Semin Urol Oncol. 2001;19:270–9.PubMedGoogle Scholar
  67. 67.
    Khurana V, Caldito G, Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case–control study of 500,000 veterans. Urology. 2008;71:118–22.PubMedGoogle Scholar
  68. 68.
    Lipworth L, Tarone RE, McLaughlin JK. Renal cell cancer among African Americans: an epidemiologic review. BMC Cancer. 2011;11:133.PubMedGoogle Scholar
  69. 69.
    Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245–57.PubMedGoogle Scholar
  70. 70.
    Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60: 615–21.PubMedGoogle Scholar
  71. 71.
    Klein EA, Thompson Jr IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549–56.PubMedGoogle Scholar
  72. 72.
    Miller 3rd ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.PubMedGoogle Scholar
  73. 73.
    Duffield-Lillico AJ, Slate EH, Reid ME, et al. for the Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst. 2003;95:1477–81.Google Scholar
  74. 74.
    Stranges S, Marshall JR, Natarajan R, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147:217–23.PubMedGoogle Scholar
  75. 75.
    Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized ­controlled trial. JAMA. 2008;300:2123–33.PubMedGoogle Scholar
  76. 76.
    Moyad MA. Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? Urology. 2002;59(4 Suppl 1):9–19.PubMedGoogle Scholar
  77. 77.
    Figueriredo JC, Grau MV, Haile RW, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst. 2009;101:432–5.Google Scholar
  78. 78.
    Cole BF, Baron JA, Sandler RS, et al. for Polyp Prevention Study Group. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297:2351–59.Google Scholar
  79. 79.
    Collin SM, Metcalfe C, REfsum H, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case–control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19: 1632–42.PubMedGoogle Scholar
  80. 80.
    Bailey RL, Mills JL, Yetley EA, et al. Unmetabolized serum folic acid and its relation to folic acid intake from diet and supplements in a nationally representative sample of adults aged  >  or =60 y in the United States. Am J Clin Nutr. 2010;92:383–9.PubMedGoogle Scholar
  81. 81.
    Clarke R, Halsey J, Lewington S, et al. for the B-vitamin Treatment Trialists’ Collaboration. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Meta-analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med. 2010;170:1622–31.Google Scholar
  82. 82.
    Giovannucci E, Chan AT. Role of vitamin and mineral supplementation and aspirin use in cancer survivors. J Clin Oncol. 2010;28:4081–5.PubMedGoogle Scholar
  83. 83.
    Lawson KA, Wright ME, Subar A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst. 2007;99:754–64.PubMedGoogle Scholar
  84. 84.
    Moyad MA. Zinc for prostate disease and other conditions: a little evidence, a lot of hype, and a significant potential problem. Urol Nurs. 2004;24:49–52.PubMedGoogle Scholar
  85. 85.
    Lamm DL, Riggs DR, Shriver JS, et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 1994;151:21–6.PubMedGoogle Scholar
  86. 86.
    Nepple KG, Lightfoot AJ, Rosevear HM, et al. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184:1915–9.PubMedGoogle Scholar
  87. 87.
    Moyad MA. Dr. Moyad’s no bogus science health advice. Ann Arbor: Ann Arbor Media Group; 2009.Google Scholar
  88. 88.
    Morris MC, Tangney CC. A potential design flaw of randomized trials of vitamin supplements. JAMA. 2011;305:1348–9.PubMedGoogle Scholar
  89. 89.
    Tighe P, Ward M, McNulty H, et al. A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy. Am J Clin Nutr. 2011;93:11–8.PubMedGoogle Scholar
  90. 90.
    Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004;164:2335–42.PubMedGoogle Scholar
  91. 91.
    Aso Y, Akazan H. Prophylactic effect of a Lactobacillus preparation on the recurrence of superficial bladder cancer. BLP Study Group. Uro Int. 1992;49:125–9.Google Scholar
  92. 92.
    Aso Y, Akaza H, Kotake T, et al. for the BLP Study Group. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol. 1995;27:104–9.Google Scholar
  93. 93.
    Naito S, Koga H, Yamaguchi A, et al. for the Kyushu University Urological Oncology Group. Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of the bladder. J Urol 2008;179:485–90.Google Scholar
  94. 94.
    Ohashi Y, Nakai S, Tsukamoto T, et al. Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int. 2002;68:273–80.PubMedGoogle Scholar
  95. 95.
    Larsson SC, Andersson SO, Johansson JE, Wolk A. Cultured milk, yogurt, and dairy intake in relation to bladder cancer risk in a prospective study of Swedish women and men. Am J Clin Nutr. 2008;88:1083–7.PubMedGoogle Scholar
  96. 96.
    di Giuseppe R, Di Castelnuovo A, Melegari C, et al. on behalf of the Moli-sani Project Investigators. Nutr Metab Cardiovasc Dis. 2010;22:347–54.Google Scholar
  97. 97.
    Solomon KR, Freeman MR. The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am. 2011;38:243–59.PubMedGoogle Scholar
  98. 98.
    Moyad MA, Klotz LH. Statin clinical trial (REALITY) for prostate cancer: an over 15-year wait is finally over thanks to a dietary supplement. Urol Clin N Am. 2011;38:325–31.Google Scholar
  99. 99.
    Moyad MA. Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part I. Curr Opin Urol. 2005;15:1–6.PubMedGoogle Scholar
  100. 100.
    Glendenning P, Zhu K, Inderjeeth C, et al. Effects of three monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility and muscle strength in older postmenopausal women: a randomized controlled trial. J Bone Miner Res. 2011; Sept 28, epub ahead of print.Google Scholar
  101. 101.
    Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303:1815–22.PubMedGoogle Scholar
  102. 102.
    Shapses SA, Manson JE. Vitamin D and prevention of cardiovascular disease disease and diabetes: why the evidence falls short. JAMA. 2011;305:2565–66.Google Scholar
  103. 103.
    Albanes D, Mondul AM, Yu K. Serum 25-hydroxy vitamin d and prostate cancer risk in a large nested case–control study. Cancer Epidemiol Biomarkers Prev. 2011;20:1850–60.PubMedGoogle Scholar
  104. 104.
    Cabler S, Agarwal A, Flint M, du Plessis SS. Obesity: modern man’s fertility nemesis. Asian J Androl. 2010;12:480–9.PubMedGoogle Scholar
  105. 105.
    Kasturi SS, Tannir J, Brannigan RE. The metabolic syndrome and male infertility. J Androl. 2008;29:251–9.PubMedGoogle Scholar
  106. 106.
    Brannian JD. Obesity and fertility. S D Med. 2011;64:251–4.PubMedGoogle Scholar
  107. 107.
    Campagne DM. Should fertilization treatment start with reducing stress? Hum Reprod. 2006;21:1651–8.PubMedGoogle Scholar
  108. 108.
    Agarwal A, Sekhon LH. The role of antioxidant therapy in the treatment of male infertility. Hum Fertil (Camb). 2010;13:217–25.Google Scholar
  109. 109.
    Showell MG, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2011;(1):CD007411.Google Scholar
  110. 110.
    Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Nutrition. 2010;26:250–4.PubMedGoogle Scholar
  111. 111.
    Balercia G, Regoli F, Armeni T, et al. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertil Steril. 2005;84:662–71.PubMedGoogle Scholar
  112. 112.
    Lenzi A, Lombardo F, Sgro P, et al. Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial. Fertil Steril. 2003;79: 292–300.PubMedGoogle Scholar
  113. 113.
    Li Z, Chen GW, Shang XJ, et al. A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue. 2005;11: 761–4.Google Scholar
  114. 114.
    Peivandi S, Abasali K, Narges M. Effects of L-carnitine on infertile men’s spermogram: a randomized clinical trial. J Reprod Infertil. 2010;10:331.Google Scholar
  115. 115.
    Lombardo F, Gandini L, Agarwal A, et al. A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertil Steril. 2002;78 Suppl 1:68–9.Google Scholar
  116. 116.
    Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden cardiac death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897–903.PubMedGoogle Scholar
  117. 117.
    Matsuzaki M, Yokoyama M, Saito Y, et al. for the JELIS investigators. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009;73:1283–90.Google Scholar
  118. 118.
    Conquer JA, Martin JB, Tummon I, Watson L, Tekpetey F. Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids. 2000;35:149–54.PubMedGoogle Scholar
  119. 119.
    Colagar AH, Marzony ET. Ascorbic acid in human seminal plasma: determination and its relationship to sperm quality. J Clin Biochem Nutr. 2009;45:144–9.PubMedGoogle Scholar
  120. 120.
    Vitamin C content in foods. Accessed 20 Mar 2011.
  121. 121.
    Moyad MA, Combs MA, Baisley JE, Evans M. Vitamin C with metabolites: additional analysis suggests favorable changes in oxalate. Urol Nurs. 2009;29:383–5.PubMedGoogle Scholar
  122. 122.
    Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men. JAMA. 2004;291(24):2978–84.PubMedGoogle Scholar
  123. 123.
    Giugliano D, Giugliano F, Esposito K. Sexual dysfunction and the Mediterranean diet. Public Health Nutr. 2006;9:1118–20.PubMedGoogle Scholar
  124. 124.
    Hannan JL, Maio MT, Komolova M, Adams MA. Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. J Sex Med. 2009;6 Suppl 3:254–61.PubMedGoogle Scholar
  125. 125.
    Horasanli K, Boylu U, Kendirci M, Miroglu C. Do lifestyle changes work for improving erectile function? Asian J Androl. 2008;10:28–35.PubMedGoogle Scholar
  126. 126.
    Esposito K, Maiorino MI, Bellastella G, et al. Determinants of female sexual dysfunction in type 2 diabetes. Int J Impot Res. 2010;22:179–84.PubMedGoogle Scholar
  127. 127.
    Esposito K, Giugliano D. Lifestyle/dietary recommendations for erectile dysfunction and female sexual dysfunction. Urol Clin North Am. 2011;38:293–301.PubMedGoogle Scholar
  128. 128.
    Maio G, Saraeb S, Marchiori A. Physical activity and PDE5 inhibitors in the treatment of erectile dysfunction: results of a randomized controlled study. J Sex Med. 2010;7:2201–8.PubMedGoogle Scholar
  129. 129.
    Khera M, Goldstein I. Erectile Dysfunction. Clinical Evidence (online); 2011.Google Scholar
  130. 130.
    Kiefer D, Pantuso T. Panax ginseng. Am Fam Phys. 2003;68:1539–42.Google Scholar
  131. 131.
    Meldrum DR, Gambone JC, Morris MA, et al. The link between erectile and cardiovascular health: the canary in the coal mine. Am J Cardiol. 2011;108:599–606.PubMedGoogle Scholar
  132. 132.
    Ledda A, Belcaro G, Cesarone MR, Dugall M, Schonlau F. Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study. BJU Int. 2010;106:1030–3.PubMedGoogle Scholar
  133. 133.
    Tsertsvadze A, Yazdl F, Fink H, et al. Oral sildenafil citrate (Viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. Urology. 2009;74:831–6.PubMedGoogle Scholar
  134. 134.
    Mulhall JP, McLaughlin TP, Hartnett JP, et al. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med. 2005;2:848–55.PubMedGoogle Scholar
  135. 135.
    Lee DJ, Cheetham P, Badani KK. Penile rehabilitation protocol after robot-assisted radical prostatectomy: assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potency. BJU Intl. 2009;105:382–8.Google Scholar
  136. 136.
    Meschi T, Nouvenne A, Borghi L. Lifestyle recommendations to reduce the risk of kidney stones. Urol Clin North Am. 2011;38:313–20.PubMedGoogle Scholar
  137. 137.
    Siener R, Jansen B, Watzer B, Hesse A. Effect of n-3 fatty acid supplementation on urinary risk factors for calcium oxalate stone formation. J Urol. 2011; 185:719–24.PubMedGoogle Scholar
  138. 138.
    Taylor EN, Stampfer MJ, Mount DB, Curhan GC. DASH-style diet and 24-hour urine composition. Clin J Am Soc Nephrol. 2010;5:2315–22.PubMedGoogle Scholar
  139. 139.
    Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol. 2009;20:2253–9.PubMedGoogle Scholar
  140. 140.
    Reiner AP, Kahn A, Eisner BH, et al. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA Study. J Urol. 2011;185:920–5.PubMedGoogle Scholar
  141. 141.
    Gur S, Limin M, Hellstrom WJ. Current status and new developments in Peyronie’s disease: medical, minimally invasive and surgical treatment options. Expert Opin Pharmacother. 2011;12:931–44.PubMedGoogle Scholar
  142. 142.
    Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178(4 Pt 1):1398–403.PubMedGoogle Scholar
  143. 143.
    Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie’s disease. BJU Int. 2002;89:895–900.PubMedGoogle Scholar
  144. 144.
    Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. 2010;22:298–309.PubMedGoogle Scholar
  145. 145.
    Wyman M, Leonard M, Morledge T. Coenzyme Q10: a therapy for hypertension and statin-induced myalgia? Cleve Clin J Med. 2010;77:435–42.PubMedGoogle Scholar
  146. 146.
    Miyakis S, Pefanis A, Tsakris A. The challenge of antimicrobial drug resistance in Greece. Clin Infect Dis. 2011;53:177–84.PubMedGoogle Scholar
  147. 147.
    Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2008;(1):CD001321.Google Scholar
  148. 148.
    Beerepoot MJ, Riet GT, Nys S, et al. Cranberries vs antibiotics to prevent urinary tract infections. Arch Intern Med. 2011;171:1270–8.PubMedGoogle Scholar
  149. 149.
    Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology. 2001; 57:26–9.PubMedGoogle Scholar
  150. 150.
    Eyre H, Kahn R, Robertson RM, et al. for the ACS/ADA/AHA Collaborative Writing Committee Members. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation. 2004;109:3244–55.Google Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Department of UrologyUniversity of Michigan Medical CenterAnn ArborUSA

Personalised recommendations